Shots:
- Pilatus Biosciences & Roche have entered into a clinical trial collaboration to evaluate PLT012 + atezolizumab for HCC pts
- Under the collaboration, Roche will supply atezolizumab (Tecentriq) for Pilatus’ P-I study of PLT012 in combination therapy for HCC, with plans to expand to other cancers
- PLT012 is a humanized mAb that blocks CD36-driven lipid uptake, targeting tumor-related immunosuppression and immune exclusion
Ref: Pilatus Biosciences | Image: Pilatus Biosciences and Roche | Press Release
Related News:- Basilea Pharmaceutica Entered Into a Licensing Deal with Venatorx Pharmaceuticals
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
